ARS Pharmaceuticals Inc. (SPRY), which launched neffy 2mg in the U.S. last month, is expected to launch the product in the EU this quarter.
neffy 2 mg is a nasal spray used to treat life-threatening, allergic emergencies including anaphylaxis, in adults and children who weigh 66 lbs or more (30 kg or more), who are at risk for or have a history of serious allergic emergencies and it was approved in the U.S. and EU in August of this year. The trade name for neffy in the EU is EURneffy. It is the first and only needle-free treatment for type I allergic reactions, including anaphylaxis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com